Treatment of cancer with specific RXR agonists

Details for Australian Patent Application No. 2006299645 (hide)

Owner Io Therapeutics, LLC

Inventors Chandraratna, Roshantha A.

Agent Davies Collison Cave

Pub. Number AU-B-2006299645

PCT Pub. Number WO2007/041398

Priority 60/722,264 30.09.05 US

Filing date 2 October 2006

Wipo publication date 12 April 2007

Acceptance publication date 3 February 2011

International Classifications

C07C 57/48 (2006.01) Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms

A61K 31/07 (2006.01)

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

A61K 31/203 (2006.01)

C07D 311/58 (2006.01) Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings

C07K 14/705 (2006.01) Peptides having more than 20 amino acids

Event Publications

24 April 2008 PCT application entered the National Phase

  PCT publication WO2007/041398 Priority application(s): WO2007/041398

20 January 2011 Assignment before Grant

  Vitae Pharmaceuticals, Inc. The application has been assigned to IO Therapeutics

3 February 2011 Application Accepted

  Published as AU-B-2006299645

2 June 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006299648-Vehicle interface

2006299642-Stabilizers and compositions and products comprising same